The FDA granted priority review designation to a new drug application for tinlarebant, a potential treatment for Stargardt disease type 1, according to a press release from Belite Bio.
August 12, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Tarsus Pharmaceuticals is entering the retina space with deals to acquire Alkeus Pharmaceuticals and iRenix Medical, according to…
The US FDA has accepted priority review of the NDA for Roche’s investigational oral SERD, giredestrant, for breast cancer.
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of…
The FDA granted orphan drug designation and fast track designation to Lacripep, according to a press release from TearSolutions.…
Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July 2026 target action date.
The FDA accepted United Therapeutics’ new drug application for ralinepag, a once-daily oral prostacyclin, for the treatment of…
